Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Trial details
- Registry ID
- NCT05537571
- Drugs studied
- SLN360
TrialRedline tracks 1 clinical trial sponsored by Silence Therapeutics plc: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsNCT05537571 | SLN360 | Completed | 2024-01-11Actual |
Names as written in the registry records.